Loading
companiesCompany
CSPC Pharmaceutical Group
CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies.
Also called: CSPC石药集团CSPC Ouyi Pharmaceutical Co., Ltd.CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Overview
Domestic leader in nanoparticle albumin-bound paclitaxel (Keaili) and pegylated liposomal doxorubicin (Duomeisu); innovative pipeline includes the Nectin-4 ADC SYS6002, the Claudin 18.2 ADC SYSA1801, an EGFR ADC and a PD-1 x VEGF programme; licences include an AI-enabled discovery collaboration with AstraZeneca (June 2025) and ADC deals. Illustrates the shift of China's big generic houses into originator research.
Headquarters
Shijiazhuang, CN
Scorecard
All companies#36of 1244 companies, score 82
- approved products +12
- phase 3 +15
- phase 1/2 +3
- targets +8
- modalities +8
- regions +6
- registry trials +30
2 approved, 5 in phase 3, 3 earlier, 4 targets, 4,726 registry studies. Formula on the scorecards page.
Type
Large pharma · 1093.HK
Stage
Public
Website
Founded
1997
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
ApprovedCytotoxic (liposomal anthracycline)
Pegylated liposomal doxorubicin · Doxil / Caelyx
Doxorubicin wrapped in a fatty bubble so it reaches tumours with less heart damage; a workhorse of relapsed ovarian cancer.
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
SYS6010 is an experimental investigational agent whose form is not stated in the registry from CSPC Megalith Biopharmaceutical in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
HB1801 is an experimental investigational agent whose form is not stated in the registry from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer, with its target not yet stated publicly.
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
JSKN003 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.
Phase 3monoclonal antibody
KN026 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.
Phase 3monoclonal antibody
JMT101 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for non-small-cell lung cancer, aimed at EGFR.
Phase 2ADC
Farletuzumab-exatecan is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials, aimed at Folate receptor alpha.
Phase 2ADC
SYS6023 is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER3.
Phase 2Monoclonal antibody
JMT203 is a monoclonal antibody from Shanghai JMT-Bio Inc., in registered phase 2 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer.
Similar pages
- CompanyAlphamab Oncology
Shares JSKN003 and the tag china.
- TreatmentTucidinostat (chidamide)
Shares Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL and the tag china.
- TrialJUPITER-06
Shares Paclitaxel / nab-paclitaxel and the tag china.
- CompanyHutchmed
Shares AstraZeneca and the tag china.
- TreatmentSavolitinib
Shares AstraZeneca and the tag china.
- TrialEfficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
fronts
drugs
Phase 2ADC
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Phase 3monoclonal antibody
Phase 2Monoclonal antibody
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
Phase 3monoclonal antibody
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane
ApprovedCytotoxic (liposomal anthracycline)
Pegylated liposomal doxorubicin · Doxil / Caelyx
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
Phase 2ADC
companies
trials
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric CancerA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsA Clinical Study of SYS6023 Combination Therapy for Advanced Breast CancerA Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian CancerA Phase I/IIa Study of SYS6041 in Patients With Advanced Solid TumorsA Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerA Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCA Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerA Study of JMT203 in Patients With Cancer CachexiaA Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid TumorsA Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous NoA Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in NA Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLClinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid TumorsDP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast CancerEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast CancerFirst-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant TumorsJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerKN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line TherapyLiposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic CancPhase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid TumorsPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsSirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine TumorsSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapySYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell CarcinomaSYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTSYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III